{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:56:05Z","timestamp":1791831365101,"version":"4.3.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.carrev.2017.10.013","type":"journal-article","created":{"date-parts":[[2017,10,28]],"date-time":"2017-10-28T00:45:25Z","timestamp":1509151525000},"page":"516-520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"PA","title":["Prevalence of high on-treatment (aspirin and clopidogrel) platelet reactivity in patients with critical limb ischemia"],"prefix":"10.1016","volume":"19","author":[{"given":"Leonardo C.","family":"Clavijo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor","family":"Al-Asady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwat","family":"Dhillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray V.","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Caro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Tun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Shavelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.carrev.2017.10.013_bb0005","article-title":"2016 AHA\/ACC guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","author":"Gerhard-Herman","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2017.10.013_bb0010","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1157\/13109651","article-title":"Peripheral artery disease: pathophysiology, diagnosis and treatment","volume":"60","author":"Serrano Hernando","year":"2007","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.carrev.2017.10.013_bb0015","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2147\/vhrm.2007.3.2.229","article-title":"Epidemiology, classification, and modifiable risk factors of peripheral arterial disease","volume":"3","author":"Shammas","year":"2007","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.carrev.2017.10.013_bb0020","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ijcard.2007.12.010","article-title":"Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events\u2014a meta-analysis","volume":"128","author":"Sofi","year":"2008","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.carrev.2017.10.013_bb0025","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1001\/archinte.167.15.1593","article-title":"Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis","volume":"167","author":"Snoep","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.carrev.2017.10.013_bb0030","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2017.10.013_bb0035","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1358\/mf.2006.28.5.990205","article-title":"Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel","volume":"28","author":"Malinin","year":"2006","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"10.1016\/j.carrev.2017.10.013_bb0040","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11239-014-1135-9","article-title":"A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease","volume":"39","author":"Price","year":"2015","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.carrev.2017.10.013_bb0045","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1538-7836.2004.01063.x","article-title":"Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases","volume":"3","author":"Aleil","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"Suppl. A","key":"10.1016\/j.carrev.2017.10.013_bb0050","first-page":"S144","article-title":"TransAtlantic Inter-Society Consensus (TASC). Section D: chronic critical limb ischaemia","volume":"19","author":"Management of peripheral arterial disease (PAD)","year":"2000","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.carrev.2017.10.013_bb0055","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.jacc.2009.11.072","article-title":"Preventing leg amputations in critical limb ischemia with below-the-knee drug-eluting stents: the PaRADISE (PReventing Amputations using Drug eluting Stents) trial","volume":"55","author":"Feiring","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2017.10.013_bb0060","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1177\/1074248414545126","article-title":"Antiplatelet therapy for peripheral arterial disease and critical limb ischemia: guidelines abound, but where are the data?","volume":"20","author":"Azarbal","year":"2015","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.carrev.2017.10.013_bb0065","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jvs.2007.11.056","article-title":"Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia","volume":"47","author":"Schanzer","year":"2008","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.carrev.2017.10.013_bb0070","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1161\/CIRCULATIONAHA.106.174526","article-title":"ACC\/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic)","volume":"113","author":"Hirsch","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2017.10.013_bb0075","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/bmj.39430.529549.BE","article-title":"Aspirin \"resistance\" and risk of cardiovascular morbidity: systematic review and meta-analysis","volume":"336","author":"Krasopoulos","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.carrev.2017.10.013_bb0080","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1538-7836.2009.03733.x","article-title":"Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel","volume":"8","author":"Bouman","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.carrev.2017.10.013_bb0085","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/FTD.0b013e3181757c59","article-title":"Assessment of VerifyNow P2Y12 assay accuracy in evaluating clopidogrel-induced platelet inhibition","volume":"3","author":"Lordkipanidze","year":"2008","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.carrev.2017.10.013_bb0090","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1540-8183.2011.00670.x","article-title":"Correlation between light transmission aggregometry, VerifyNow P2Y12, and VASP-P platelet reactivity assays following percutaneous coronary intervention","volume":"24","author":"Gaglia","year":"2011","journal-title":"J Interv Cardiol"},{"key":"10.1016\/j.carrev.2017.10.013_bb0095","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejvs.2016.04.019","article-title":"High on-treatment platelet reactivity in peripheral arterial disease: a pilot study to find the optimal test and cut off values","volume":"52","author":"Leunissen","year":"2016","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.carrev.2017.10.013_bb0100","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1016\/j.jacc.2013.03.036","article-title":"Platelet responsiveness to clopidogrel treatment after peripheral endovascular procedures: the PRECLOP study: clinical impact and optimal cutoff value of on-treatment high platelet reactivity","volume":"61","author":"Spiliopoulos","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2017.10.013_bb0105","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.carrev.2017.10.013_bb0110","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with and without aspirin in stable cardiovascular disease","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838917304037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838917304037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:13:29Z","timestamp":1761560009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838917304037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S1553838917304037"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2017.10.013","relation":{},"ISSN":["1553-8389"],"issn-type":[{"value":"1553-8389","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of high on-treatment (aspirin and clopidogrel) platelet reactivity in patients with critical limb ischemia","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2017.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}